Aslan slashes headcount following midphase failure by Nick Paul Taylor Wednesday, January 30, 2019 The layoffs are expected to halve Aslan’s operational costs, extending its runway as it heads toward upcoming readouts.
Aslan fails to roar as lead drug flunks phase 2 trial by Phil Taylor Monday, January 14, 2019 Aslan has been hit by the news that its lead drug varlitinib missed the mark in a gastric cancer trial, sending its shares down almost 16%.
J&J inks Singapore public-private partnership in myopia research by Conor Hale Friday, November 16, 2018 Johnson & Johnson Vision inked a $26.35 million collaboration with the Singapore Eye Research institute focused on treating nearsightedness.
Synthetic polymers could tackle resistant superbugs by Amirah Al Idrus Friday, March 9, 2018 Synthetic polymers invented by IBM, which killed five types of superbugs, could be the answer to antibiotic resistance.
Biosensorix pens pact to develop rapid dengue, stroke tests by Nick Paul Taylor Monday, February 26, 2018 Biosensorix's new collaboration will give it access to an electrochemical lateral flow immunosensor.
Temasek unit backs dialysis startup’s CE mark push by Nick Paul Taylor Tuesday, December 12, 2017 The product is a small titanium device that is implanted beneath the skin to provide access to an arteriovenous fistula.
Tracking outbreaks with bacteria-spreading flies by Arlene Weintraub Monday, November 27, 2017 Sequencing the genes of 116 houseflies led scientists in Singapore to propose using the insects as early warning systems for emerging outbreaks.
New discoveries in opioid addiction and heart disease—News of Note by Arlene Weintraub Monday, August 21, 2017 The past week brought new discoveries related to opioid addiction, heart failure and inflammation.
Zebra strikes deal to bring AI image analysis to Asia, Africa by Nick Paul Taylor Friday, July 7, 2017 Zebra Medical Vision has teamed up with India’s TRS to bring its AI-enabled image analysis system to 20 countries in Asia and Africa.
WuXi NextCODE lands $75M Series B led by Temasek and Yunfeng Capital by Angus Liu Tuesday, May 2, 2017 Singapore’s state-owned investment firm Temasek and Chinese internet tycoon Jack Ma-backed Yunfeng Capital have led a $75 million Series B into WuXi NextCODE.
